Immunology · Biosimilar
The FDA's acceptance of the supplemental application for HADLIMA signifies a critical step in the competitive landscape of biosimilars, particularly against AbbVie's Humira. This development may influence market dynamics and pricing strategies as Humira approaches patent expiration.
Explore aggregated signals, assets, and competitive context for organizations linked to this signal.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/11/2026, 6:33:58 AM
Assessment confidence: 56% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.
The FDA's acceptance of the supplemental application for HADLIMA signifies a critical step in the competitive landscape of biosimilars, particularly against AbbVie's Humira. This development may influence market dynamics and pricing strategies as Humira approaches patent expiration. Regulatory context from FDA (FDA AP — HADLIMA (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (4 high-relevance).
Portfolio teams should evaluate the potential market impact and pricing strategies for HADLIMA in relation to Humira's upcoming patent expirations. The strongest clinical anchor is The Effect of SuJok Application on Dysmenorrhea and Quality of Life in Young People With Primary Dysmenorrhea: (ClinicalTrials.gov), moderate corpus alignment. In Immunology · Biosimilar, 4 regulatory and 3 competitive items passed relevance filtering for AbbVie.
The most relevant competitive pressure comes from FDA Approves Supplemental Application for RINVOQ LQ by AbbVie (Humanexa Signals) — entity match (abbvie). Secondary pressure from FDA Approves Supplemental Application for XELJANZ XR by Pfizer. This acceptance may enhance Samsung Bioepis's position in the biosimilar market, particularly against AbbVie's Humira.
Regulatory risk is concentrated around FDA AP — HADLIMA (SUPPL) (FDA). Entity match (hadlima). Relevant agencies in corpus: FDA, MHRA. The acceptance of the supplemental application indicates a positive regulatory trajectory for HADLIMA, but the final approval and market entry will be critical to monitor.
Access, new active substance and biosimilar work sharing initiatives
MHRAmedium relevance
Moderate corpus alignment
FDA document
View sourceIND Application Reporting: IND Safety Reports
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceInvestigational New Drug (IND) Application
FDAmedium relevance
Moderate corpus alignment
FDA document
View sourceThe Effect of SuJok Application on Dysmenorrhea and Quality of Life in Young People With Primary Dysmenorrhea:
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceThe Effect of Superficial Cervical Block Application on Postoperative Opioid Consumption in Patients Undergoing Anterior Cervical Discectomy Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceAdjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceTraditional Chinese Medicine Patch for Cancer-Related Fatigue During Radiotherapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Approves Supplemental Application for RINVOQ LQ by AbbVie
Humanexa Signalshigh relevance
Entity match (abbvie)
FDA Approves Supplemental Application for XELJANZ XR by Pfizer
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
A 3.6:1 myo-inositol to D-chiro-inositol ratio and antioxidant-based food supplement before IVF improves fertility in women with PCOS: a pilot observational retrospective cohort study.
PubMedhigh relevance
Mechanism alignment (IO )
FDA document
View sourceSelected immunoendocrine and performance adaptations to upper-body plyometric training and β-alanine supplementation in male swimmers.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceRarely reported cases of hepatotoxicity associated with turmeric- and curcuminoid-containing dietary supplements: a comprehensive review by USP.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of carnosine supplementation on physical endurance: a placebo-controlled randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceThe application of growth factors in bone tissue engineering delivery systems and collaborative innovation strategies.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's acceptance of the supplemental application for HADLIMA signifies a critical step in the competitive landscape of biosimilars, particularly against AbbVie's Humira. This development may influence market dynamics and pricing strategies as Humira approaches patent expiration.
The introduction of HADLIMA could capture market share from Humira, impacting revenue streams for both Samsung Bioepis and AbbVie as they navigate pricing and market positioning.
The acceptance of the supplemental application indicates a positive regulatory trajectory for HADLIMA, but the final approval and market entry will be critical to monitor.
Monitor the timeline for FDA decision and any subsequent market entry strategies from Samsung Bioepis.
Track for follow-up milestones; no immediate action required.